SecBot SecBot
8-K ·Filed May 15, 2026

PROK

PROKIDNEY CORP.
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago SEC0001193125-26-225848
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

No new clinical data or guidance change, the stock will trade on the unchanged PROACT 1 timeline (enrollment mid-2026, data Q2 2027). The updated 80% powering assumption for the surrogate endpoint is a minor technical clarification, not a de-risking event. Monitor for enrollment completion announcement in the coming months as the next catalyst.

DirectionNeutral
Confidencehigh
Horizonmonths

Price Chart

Loading chart...

Executive Summary

ProKidney reported Q1 2026 financial results that were in line with consensus, with a net loss of $20.0M available to Class A common stockholders ($-0.14 EPS) versus the $-0.14 estimate. The company reiterated its key clinical milestones: Phase 3 PROACT 1 enrollment completion mid-2026 and pivotal eGFR slope data in Q2 2027. Cash burn accelerated to $41.7M in operating cash flow (vs $29.6M in Q1 2025), reducing the cash runway to $224.9M, still supporting operations into mid-2027. The filing is neutral, no new data, no guidance change, and the clinical timeline remains on track.

Key Financial Metrics

EPS
−$0.14
est −$0.14 · 0.0%
Revenue
$226.0K
est $100.0K · +126.0% · -1.7% YoY
Rating
in line

Key Facts

  • Q1 2026 net loss available to Class A common stockholders was $20.0M ($-0.14 EPS), in line with consensus of $-0.14
  • Revenue was $226K, essentially flat vs $230K in Q1 2025
  • Cash, cash equivalents and marketable securities totaled $224.9M at March 31, 2026, down from $270.0M at December 31, 2025
  • Operating cash flow was -$41.7M in Q1 2026 vs -$29.6M in Q1 2025, a 41% increase in cash burn
  • Phase 3 PROACT 1 enrollment for accelerated approval efficacy analysis remains on track for mid-2026, with pivotal topline results expected Q2 2027
  • The statistical powering assumption for the surrogate endpoint (eGFR slope) was updated to 80% (from prior 90%) in the 8-K Item 8.01
  • Cash runway guidance unchanged: operations funded into mid-2027

Financial Impact

Q1 2026 net loss of $20.0M on $226K revenue; cash burn increased 41% YoY to $41.7M operating cash flow; cash position $224.9M provides runway into mid-2027

cashnet lossoperating cash flow

Risk Factors

  • Cash burn accelerated to $41.7M/quarter, reducing runway faster than prior run-rate implied
  • Phase 3 PROACT 1 trial failure risk remains binary, no interim data to de-risk
  • No new financing announced; if enrollment or data timeline slips, the company may need to raise capital before mid-2027

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
67% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-225848
Document: prok-20260515.htm0001193125-26-225848
Document: prok-ex99_2.htm0001193125-26-225848
Document: 0001193125-26-225848-index-headers.html0001193125-26-225848
Document: 0001193125-26-225848-index.html0001193125-26-225848
Document: 0001193125-26-225848.txt0001193125-26-225848
8-K Data (Synthetic)0001193125-26-225848

Track record

13 reports on PROK

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +13.51% at T+1 after the Oct 29, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Bearish 7/10 Entry $1.05 to $1.04 Now $1.04 +0.48% ▲ +0.48% −1.43% vs SPY
  2. Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
  3. Nov 12, 20265d ago EFFECT Bearish 5/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
  4. Nov 9, 20267d ago 8-K Neutral 3/10 Entry $1.15 to $1.11 Now $1.04 −9.57% ▼ −3.48% −3.11% vs SPY
  5. Oct 29, 202618d ago 8-K Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
  6. Oct 29, 202618d ago S-3 Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
  7. Oct 22, 202625d ago Press Release Neutral 3/10 Entry $1.43 to $1.41 Now $1.04 −27.27% ▼ −1.40% −0.88% vs SPY
  8. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  9. Aug 10, 202614w ago Press Release Neutral 5/10 Entry $1.61 to $1.48 Now $1.04 −35.40% ▼ −8.07% −8.32% vs SPY
  10. May 15, 202626w ago 8-K Neutral 4/10 Viewing No price data
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026